SequelSEC

ARTELO BIOSCIENCES, INC. ARTL

Pharmaceutical Preparations · CIK 0001621221 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$11.40M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

ARTELO BIOSCIENCES, INC. (ARTL) reported net income of -$12.88M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ARTELO BIOSCIENCES, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ARTELO BIOSCIENCES, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312021-08-312020-08-312019-08-312018-08-312017-08-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$11.40M-$10.11M-$9.93M-$10.29M-$9.42M-$7.44M-$4.69M-$3.21M-$2.34M-$232.79K
Net income-$12.88M-$9.83M-$9.29M-$10.08M-$9.41M-$7.44M-$4.66M-$2.17M-$2.34M-$234.89K
Research & development$5.42M$5.99M$5.70M$4.32M$3.78M$2.84M$1.92M$1.09M$1.25MUnavailable
Weighted-average diluted sharesshares 1.03MUnavailableshares 2.96MUnavailableUnavailableUnavailableUnavailableshares 2.17Mshares 1.28Mshares 1.93M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0$0$0$0$0$0$0$0
Diluted EPS$-12.52$-18.30$-3.14UnavailableUnavailableUnavailableUnavailable$-1.46$-1.84Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$5.98M$4.12M$4.23M$5.96M$5.63M$4.60M$1.79M$952.33K$508.28K$110.86K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

ARTELO BIOSCIENCES, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312021-08-312020-08-312019-08-312018-08-312017-08-31
Cash & equivalents$600.00KUnavailableUnavailable$6.89M$12.16M$6.63M$2.14M$4.42M$337.42K$572.78K
Total assets$2.80M$4.70M$13.04M$20.42M$28.25M$12.64M$4.38M$6.48M$397.00K$574.28K
Current assets$695.00K$2.56M$10.98M$18.32M$24.61M$10.32M$2.34M$4.44M$396.44K$574.28K
Total liabilities$4.07M$1.84M$1.29M$1.02M$1.08M$593.00K$501.00KUnavailableUnavailableUnavailable
Current liabilities$4.04M$1.77M$1.29M$998.00K$1.03M$526.00K$501.00K$1.02M$531.97K$29.44K
Total equity incl. NCI-$1.27M$2.86M$11.75M$19.40M$27.17M$12.04M$3.88M$5.46M-$134.97K$544.84K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$639.42KUnavailableUnavailable

Cash flow

ARTELO BIOSCIENCES, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312021-08-312020-08-312019-08-312018-08-312017-08-31
Operating cash flow-$8.52M-$8.35M-$8.21M-$8.01MUnavailable-$6.14M-$4.35M-$2.79M-$1.61M-$216.82K
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$62.00K$7.77M$3.51M$2.96MUnavailable-$3.44M$0-$1.50M-$845Unavailable
Financing cash flow$6.87M$112.00K$567.00K$0Unavailable$14.11M$1.98M$8.38M$1.39M$785.35K
Net change in cash-$1.74M-$477.00K-$4.07M-$5.27MUnavailable$4.49M-$2.28M$4.09M-$235.35K$568.53K
Stock-based compensation$1.14M$818.00K$1.02M$2.46MUnavailable$1.53M$381.00K$425.11K$290.00K$3.33K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

ARTELO BIOSCIENCES, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312021-08-312020-08-312019-08-312018-08-312017-08-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.17x1.44x8.51x18.36x23.96x19.61x4.66x4.35x0.75x19.51x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ARTL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.